Tony Jourdan1, Joshua K Park1, Zoltán V Varga2, János Pálóczi2, Nathan J Coffey1, Avi Z Rosenberg3,4, Grzegorz Godlewski1, Resat Cinar1, Ken Mackie5, Pal Pacher2, George Kunos1. 1. Laboratory of Physiologic Studies, National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institutes of Health (NIH), Bethesda, Maryland. 2. Laboratory of Cardiovascular Physiology and Tissue Injury, NIH/NIAAA, Bethesda, Maryland. 3. Department of Pathology, Johns Hopkins University, Baltimore, Maryland. 4. Kidney Diseases Section, National Institute on Diabetes, Digestive, and Kidney Diseases (NIDDK), NIH, Bethesda, Maryland. 5. Department of Psychological and Brain Sciences, Indiana University, Bloomington, Indiana.
Abstract
AIMS: To determine the specific role of podocyte-expressed cannabinoid-1 receptor (CB1 R) in the development of diabetic nephropathy (DN), relative to CB1 R in other renal cell types. MATERIAL AND METHODS: We developed a mouse model with a podocyte-specific deletion of CB1 R (pCB1Rko) and challenged this model with streptozotocin (STZ)-induced type-1 DN. We also assessed the podocyte response to high glucose in vitro and its effects on CB1 R activation. RESULTS: High glucose exposure for 48 hours led to an increase in CB1 R gene expression (CNR1) and endocannabinoid production in cultured human podocytes. This was associated with podocyte injury, reflected by decreased podocin and nephrin expression. These changes could be prevented by Cnr1-silencing, thus identifying CB1R as a key player in podocyte injury. After 12 weeks of chronic hyperglycaemia, STZ-treated pCB1Rko mice showed elevated blood glucose similar to that of their wild-type littermates. However, they displayed less albuminuria and less podocyte loss than STZ-treated wild-type mice. Unexpectedly, pCB1Rko mice also have milder tubular dysfunction, fibrosis and reduction of cortical microcirculation compared to wild-type controls, which is mediated, in part, by podocyte-derived endocannabinoids acting via CB1 R on proximal tubular cells. CONCLUSIONS: Activation of CB1 R in podocytes contributes to both glomerular and tubular dysfunction in type-1 DN, which highlights the therapeutic potential of peripheral CB1 R blockade.
AIMS: To determine the specific role of podocyte-expressed cannabinoid-1 receptor (CB1 R) in the development of diabetic nephropathy (DN), relative to CB1 R in other renal cell types. MATERIAL AND METHODS: We developed a mouse model with a podocyte-specific deletion of CB1 R (pCB1Rko) and challenged this model with streptozotocin (STZ)-induced type-1 DN. We also assessed the podocyte response to high glucose in vitro and its effects on CB1 R activation. RESULTS: High glucose exposure for 48 hours led to an increase in CB1 R gene expression (CNR1) and endocannabinoid production in cultured human podocytes. This was associated with podocyte injury, reflected by decreased podocin and nephrin expression. These changes could be prevented by Cnr1-silencing, thus identifying CB1R as a key player in podocyte injury. After 12 weeks of chronic hyperglycaemia, STZ-treated pCB1Rko mice showed elevated blood glucose similar to that of their wild-type littermates. However, they displayed less albuminuria and less podocyte loss than STZ-treated wild-type mice. Unexpectedly, pCB1Rko mice also have milder tubular dysfunction, fibrosis and reduction of cortical microcirculation compared to wild-type controls, which is mediated, in part, by podocyte-derived endocannabinoids acting via CB1 R on proximal tubular cells. CONCLUSIONS: Activation of CB1 R in podocytes contributes to both glomerular and tubular dysfunction in type-1 DN, which highlights the therapeutic potential of peripheral CB1 R blockade.
Authors: Ehtesham Arif; Ashish K Solanki; Pankaj Srivastava; Bushra Rahman; Brian R Tash; Lawrence B Holzman; Michael G Janech; René Martin; Hans-Joachim Knölker; Wayne R Fitzgibbon; Peifeng Deng; Milos N Budisavljevic; Wing-Kin Syn; Cindy Wang; Joshua H Lipschutz; Sang-Ho Kwon; Deepak Nihalani Journal: Kidney Int Date: 2019-03-04 Impact factor: 10.612
Authors: Mohanraj Rajesh; Partha Mukhopadhyay; Sándor Bátkai; Muhammad Arif; Zoltán V Varga; Csaba Mátyás; Janos Paloczi; Andrea Lehocki; György Haskó; Pal Pacher Journal: Geroscience Date: 2022-04-22 Impact factor: 7.581
Authors: F Barutta; S Bellini; R Mastrocola; R Gambino; F Piscitelli; V di Marzo; B Corbetta; V K Vemuri; A Makriyannis; L Annaratone; G Bruno; G Gruden Journal: Br J Pharmacol Date: 2018-11-06 Impact factor: 8.739